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A B S T R A C T
Purpose
Lenalidomidemaintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated
prolonged progression-free survival (PFS) versus placebo or observation in several randomized
controlled trials (RCTs) of patients with newly diagnosedmultiple myeloma (NDMM). All studies had
PFS as the primary end point, and nonewere powered for overall survival (OS) as a primary end point.
Thus, a meta-analysis was conducted to better understand the impact of lenalidomide maintenance
in this setting.
Patients and Methods
The meta-analysis was conducted using primary-source patient-level data and documentation
from three RCTs (Cancer and Leukemia Group B 100104, Gruppo Italiano Malattie Ematologiche
dell’Adulto RV-MM-PI-209, and Intergroupe Francophone du Myélome 2005-02) that met the fol-
lowing prespecified inclusion criteria: an RCT in patients with NDMM receiving ASCT followed by
lenalidomide maintenance versus placebo or observation with patient-level data available and
achieved database lock for primary efficacy analysis.
Results
Overall, 1,208 patients were included in the meta-analysis (605 patients in the lenalidomide
maintenance group and 603 in the placebo or observation group). Themedian PFS was 52.8 months
for the lenalidomide group and 23.5 months for the placebo or observation group (hazard ratio, 0.48;
95% CI, 0.41 to 0.55). At a median follow-up time of 79.5 months for all surviving patients, the
median OS had not been reached for the lenalidomide maintenance group, whereas it was
86.0 months for the placebo or observation group (hazard ratio, 0.75; 95%CI, 0.63 to 0.90; P = .001).
The cumulative incidence rate of a second primary malignancy before disease progression was
higher with lenalidomide maintenance versus placebo or observation, whereas the cumulative
incidence rates of progression, death, or death as a result ofmyelomawere all higherwith placebo or
observation versus lenalidomide maintenance.
Conclusion
This meta-analysis demonstrates a significant OS benefit and confirms the PFS benefit with
lenalidomide maintenance after ASCT in patients with NDMM when compared with placebo or
observation.
J Clin Oncol 35:3279-3289. © 2017 by American Society of Clinical Oncology
INTRODUCTION
After induction therapy, patients with newly di-
agnosed multiple myeloma (NDMM) may be
treated with high-dose melphalan (HDM) and
autologous stem-cell transplantation (ASCT).1-4
ASCT is not curative, and most patients will ex-
perience progressive disease (PD),5-8 even patients
who attain a complete response.9-11 Strategies to
delay PD include achieving a deep response after
ASCT12-15 and sustaining response with main-
tenance therapy to provide long-term disease
control.9,16,17
Effective maintenance therapy should be
convenient for the patient, extend remission, and
have a tolerable safety profile.3,18 The immuno-
modulatory drug lenalidomide has been shown to
Author affiliations and support information
(if applicable) appear at the end of this
article.
Published at jco.org on July 25, 2017.
Processed as a Rapid Communication
manuscript.
Clinical trial information: NCT00551928,
NCT00551928, NCT00430365.
Corresponding author: Philip L. McCarthy,
MD, Blood and Marrow Transplant
Program, Roswell Park Cancer Institute,
Elm and Carlton Streets, Buffalo, NY
14263; e-mail: philip.mccarthy@
roswellpark.org.











© 2017 by American Society of Clinical Oncology 3279
VOLUME 35 • NUMBER 29 • OCTOBER 10, 2017
Downloaded from ascopubs.org by 31.157.41.148 on March 5, 2020 from 031.157.041.148
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
improve progression-free survival (PFS) and overall survival (OS)
in patients with NDMM and relapsed or refractory multiple
myeloma (MM).2,19-24 Lenalidomide modulates the immune
response, inhibits MM growth, and is suitable for maintenance
therapy after ASCT.1,3,18,25 In three studies,2,19,20 lenalidomide
maintenance after ASCT reduced the risk of progression or death by
50% to 58% versus placebo or observation, and one of these studies
showed a significant OS improvement.19 The primary end point of
these studies was PFS, and the studies were not powered for a primary
OS end point. In addition, second primary malignancies (SPMs)
were reported in patients receiving lenalidomide maintenance after
HDMandASCT.19,20 Ameta-analysis was conducted at the request of
the US Food and Drug Administration to evaluate the effect of post-
ASCT lenalidomide maintenance on outcomes, including OS, in
patients with NDMM.
PATIENTS AND METHODS
Study Identification and Selection
We examined all randomized controlled trials (RCTs) evaluating
maintenance treatment with lenalidomide after HDMand ASCT. Inclusion
criteria included RCT in patients with NDMM receiving post-ASCT
lenalidomide before progression; maintenance comparing a lenalido-
mide arm to a placebo or observation arm; achieved database lock for the
primary efficacy analysis; and primary-source patient-level data or available
documentation. A search of the PubMed database using the keywords
“lenalidomide,” “maintenance,” and “myeloma” found no other studies. We
identified 17 studies (Data Supplement) and the following three studies met
the prespecified inclusion criteria: Cancer and Leukemia Group B (CALGB)
100104 (A Phase III Randomized, Double-Blind Study of Maintenance
Therapy With Lenalidomide or Placebo Following Autologous Stem Cell
Transplantation for Multiple Myeloma)19; Gruppo Italiano Malattie Ema-
tologiche dell’Adulto (GIMEMA) RV-MM-PI-209 (A Phase III, Multicenter,
Randomized, Controlled Study to Determine the Efficacy and Safety of
Lenalidomide, Melphalan, and Prednisone Versus Melphalan (200 mg/m2)
Followed by Stem Cell Transplant in Patients with Newly Diagnosed Multiple
Myeloma)2; and Intergroupe Francophone du Myélome (IFM) 2005-02
(Relevance of Maintenance Therapy Using Lenalidomide After Autologous
Stem Cell Transplantation Patients Under the Age of 65)20. The Myeloma XI
trial (Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and
Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma
Patients)26 had not completed accrual at the data cutoff date, and the other 13
studies did not compare lenalidomide maintenance with placebo or
observation. Additional study details are provided in the Data Supplement.
The human investigations for the CALGB study were performed after
approval by a local or central human investigations committee and in
accordance with an assurance filed with and approved by the Department
of Health and Human Services. The IFM and GIMEMA studies were
performed after approval by a local or central human investigations
committee in accordance with the European Medicines Agency. All data
were anonymized to protect the identities of patients involved in the
research. All investigators obtained informed consent from each partici-
pant or each participant’s guardian.
Outcome Measures
The primary end point for the meta-analysis was OS. Other analyses
included PFS, PFS after next therapy (PFS2), duration of maintenance
treatment, time to second antimyeloma treatment, and safety. Individual
analyses of OS, PFS, and PFS2 for each study were performed. All analyses
used patient-level data from each study. Additional end point analytic
details are provided in the Data Supplement.
Statistical Analysis
A 20-month improvement in median OS from 70 months for the
placebo or observation control group to 90 months in the lenalidomide
maintenance group, representing a hazard ratio (HR) of 0.78, was con-
sidered clinically relevant. March 1, 2015 was the cutoff date for the meta-
analysis on the basis of number of events required. All patients were
evaluated on an intent-to-treat (ITT) basis after ASCT. Additional
methods, including sensitivity, heterogeneity, and exploratory analytic
details, are presented in the Data Supplement.
RESULTS
Patient Demographics
A total of 1,208 patients composed the ITT population; 605
patients were in the lenalidomide maintenance group, and 603
patients were in the placebo or observation group (Data Sup-
plement). The ITT population included all patients who were
randomly assigned to lenalidomide versus placebo or observation
and who received HDM or ASCT, regardless of whether they
received maintenance therapy.
As of the March 1, 2015, data cutoff, the median follow-up
time for all surviving patients was 79.5 months (range, 0.0 to
114.3 months). Patient demographics and disease-related char-
acteristics were generally balanced based on available data, except
for International Staging System (ISS) disease stage, cytogenetics,
and renal function, which favored the placebo or observation
group (P , .1; Table 1). The median age was approximately 58
years. Additional details on patient demographics and disease
evaluation after ASCT and before maintenance therapy are pro-
vided in the Data Supplement. Maintenance treatment duration
was affected by study changes within the CALGB study (allowing
crossover from placebo to lenalidomide at unblinding before PD)
and the IFM study (stopping maintenance in 119 patients without
PD). Maintenance therapy durations are listed in Table 2. The
percentages of patients receiving lenalidomide for $ 4 years were
24.1% in CALGB, 3.6% in IFM (which includes 2 cycles of lena-
lidomide consolidation), and 42.9% in the GIMEMA study. The
mean treatment duration was 28 months with lenalidomide
maintenance and 22 months with placebo or observation (Table 2).
PFS
In this meta-analysis, the significant PFS improvement ob-
served with lenalidomide maintenance versus placebo or obser-
vation was confirmed. The median PFS time was 52.8 months for
the lenalidomide group and 23.5 months for the placebo or ob-
servation group. The risk of progression or death was reduced by
52%with lenalidomide maintenance versus placebo or observation
(HR, 0.48; 95% CI, 0.41 to 0.55; Fig 1A). Results were consistent
when alternative censoring rules were applied (Data Supplement).
The PFS improvement with lenalidomide maintenance versus
placebo or observation was confirmed in each study (Fig 1B) and
was seen in all subgroups that had data available from all three
studies (Fig 1C). Subgroup analysis of data not available from all
three studies is presented in the Data Supplement. Lenalidomide
maintenance improved PFS in all subgroups, including patients
with high-risk cytogenetics; however, the majority of patients did
not have available cytogenetic data.
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OS
As of the March 1, 2015, data cutoff, 490 deaths occurred in
both cohorts. Median OS was not reached in the lenalidomide
maintenance group and was 86.0 months in the placebo or ob-
servation group (HR, 0.75; 95% CI, 0.63 to 0.90; P = .001),
representing a 25% reduction in the risk of death with lenalido-
mide maintenance versus placebo or observation (Fig 2A). Fisher’s
combination test confirmed the significant OS benefit with
lenalidomide maintenance versus placebo or observation (P = .001).
The 7-year survival rate was 62% with lenalidomide maintenance
and 50%with placebo or observation. At the median follow-up time
of 79.5 months, 64% and 54% of patients were alive in the lena-
lidomide maintenance and placebo or observation groups, re-
spectively. The proportional hazards (PH) assumption was tested
using the time-dependent covariate in the PH Cox model; the
proportionality was not significant (P = .21). The graphical check of
the PH assumption using the 2log (2log) plot of the estimated
survival function for each treatment group revealed the same results.
The OS subgroup analyses are shown in Figure 2B. Except for
patients with ISS disease stage III, the HRs for the subgroup analyses
favor lenalidomide maintenance. Patients with better responses ($
very good partial response) after HDM or ASCT seemed to have
Table 1. Demographics and Disease-Related Characteristics at Diagnosis (intent-to-treat population)
Characteristic*
No. of Patients (%)























Median (range) 58.0 (29.0-71.0) 58.0 (39.0-71.0) 57.5 (22.7-68.3) 58.1 (32.3-67.0) 57.9 (35.5-65.1) 56.2 (40.1-66.0) 58.0 (22.7-71.0) 57.9 (32.3-71.0)
# 59 131 (56.7) 133 (58.1) 198 (64.5) 194 (63.2) 43 (64.2) 48 (71.6) 372 (61.5) 375 (62.2)
$ 60 100 (43.3) 96 (41.9) 109 (35.5) 113 (36.8) 24 (35.8) 19 (28.4) 233 (38.5) 228 (37.8)
Male 121 (52.4) 129 (56.3) 169 (55.0) 181 (59.0) 32 (47.8) 39 (58.2) 322 (53.2) 349 (57.9)
Race
White 175 (75.8) 171 (74.7) — — 65 (97.0) 67 (100) 240 (39.7) 238 (39.5)
Nonwhite 42 (18.2) 47 (20.5) — — 2 (3.0) 0 44 (7.3) 47 (7.8)
Missing data 14 (16.1) 11 (4.8) 307 (100) 307 (100) 0 0 321 (53.1) 318 (52.7)
ISS stage‡§k
I 62 (26.8) 85 (37.1) 128 (41.7) 143 (46.6) 35 (52.2) 41 (61.2) 225 (37.2) 269 (44.6)
II 58 (25.1) 46 (20.1) 104 (33.9) 107 (34.9) 24 (35.8) 17 (25.4) 186 (30.7) 170 (28.2)
III 39 (16.9) 35 (15.3) 66 (21.5) 46 (15.0) 8 (11.9) 9 (13.4) 113 (18.7) 90 (14.9)
Missing data 72 (31.2) 63 (27.5) 9 (2.9) 11 (3.6) 0 0 81 (13.4) 74 (12.3)
Extramedullary
disease
Yes 54 (23.4) 69 (30.1) 30 (9.8) 28 (9.1) 10 (14.9) 10 (14.9) 94 (15.5) 107 (17.7)
No 160 (69.3) 149 (65.1) 277 (90.2) 278 (90.6) 57 (85.1) 57 (85.1) 494 (81.7) 484 (80.3)





Yes — — 41 (13.4) 24 (7.8) 15 (22.4) 12 (17.9) 56 (9.3) 36 (6.0)
No — — 202 (65.8) 216 (70.4) 30 (44.8) 27 (40.3) 232 (38.3) 243 (40.3)
Missing data — — 64 (20.8) 67 (21.8) 22 (32.8) 28 (41.8) 317 (52.4) 324 (53.7)
Lactate
dehydrogenase
Normal — — 208 (67.8) 220 (71.7) 62 (92.5) 63 (94.0) 270 (44.6) 283 (46.9)
. ULN — — 40 (13.0) 41 (13.4) 5 (7.5) 4 (6.0) 45 (7.4) 45 (7.5)
Missing data — — 59 (19.2) 46 (15.0) 0 0 290 (47.9) 275 (45.6)
Creatinine clearance,
mL/mink¶
, 50 11 (4.8) 9 (3.9) 45 (14.7) 25 (8.1) 4 (6.0) 3 (4.5) 60 (9.9) 37 (6.1)
$ 50 60 (26.0) 64 (27.9) 204 (66.4) 232 (75.6) 63 (94.0) 64 (95.5) 327 (54.0) 360 (59.7)
Missing data 160 (69.3) 156 (68.1) 58 (18.9) 50 (16.3) 0 0 218 (36.0) 206 (34.2)
NOTE. Dash indicates not reported.
Abbreviations: CALGB, Cancer and Leukemia Group B; GIMEMA, Gruppo Italiano Malattie Ematologiche dell’Adulto; IFM, Intergroupe Francophone du Myélome; ISS,
International Staging System; Len, lenalidomide; ULN, upper limit of normal.
*Race was not collected in the IFM 2005-02 study, and lactate dehydrogenase and cytogenetics data were not available for the CALGB 100104 study.
†For the CALGB 100104 and IFM 2005-02 studies, age at random assignment was available or used. For the GIMEMA study, only age at diagnosis was available.
‡P, .1 for the comparison of ISS stages I, II, and III individually. The ISS stage was based on b2-microglobulin and albumin at diagnosis for the GIMEMA RV-MM-PI-209
and IFM 2005-02 studies and at registration for the CALGB 100104 study.
§P, .1 for the comparison between the lenalidomidemaintenance arm and placebo arm in the CALGB study using the t test for continuous variables and Fisher’s exact
test for categorical variables.
kP , .1 for the comparison between the lenalidomide maintenance group and placebo or observation group in the pooled analysis using the t test for continuous
variables and Fisher’s exact test for categorical variables.
¶P, .1 for the comparison between the lenalidomide maintenance arm and placebo arm in the IFM 2005-02 study using the t test for continuous variables and Fisher’s
exact test for categorical variables.
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more favorable outcomes with lenalidomidemaintenance. Themost
favorable OS benefit with lenalidomide maintenance was observed
in patients who received a lenalidomide-based induction treatment
(Fig 2C). Subgroup analysis of data not available for all three studies
is presented in the Data Supplement. An OS improvement with
lenalidomide maintenance was not seen in the following diagnostic
subgroups: elevated lactate dehydrogenase, low creatinine clearance,
and adverse-risk cytogenetics; however, not all patients had available
information.
Heterogeneity and Exploratory Analyses
The Pignon heterogeneity test indicated a significant differ-
ence in quantitative treatment effect across studies (P = .047). No
qualitative heterogeneity in OS was found using the Gail-Simon
test (P = .75), indicating no directional difference in treatment
effect. Thus, the HRs of the individual studies all favored lenali-
domide maintenance treatment (Fig 2D). The heterogeneity ob-
served is driven by the difference in magnitude of the treatment
effect among the studies. A simplified multivariate analysis with
treatment, study, and treatment by study interaction in the model
revealed similar results; the heterogeneity in OS was mainly a result
of differences between the CALGB and IFM studies (P = .015 for
treatment by study [CALGB v IFM] interaction). There was no
significant heterogeneity in OS between CALGB and GIMEMA
(P = .525 for treatment by study [CALGB v GIMEMA] in-
teraction). There were differences between the three studies
regarding pre- and post-ASCT patient characteristics and treatment.
These differences include prestudy patient characteristics, induction
regimens, consolidation therapies (Data Supplement), and second-
line therapies (Data Supplement), as well as changes in study
conduct such as post-ASCT lenalidomide consolidation in the IFM
trial, crossover from placebo to lenalidomide after unblinding
in the CALGB trial, and stopping of lenalidomide maintenance
therapy in the IFM trial (Data Supplement). With extended follow-
up (February 1, 2016), lenalidomide maintenance reduced the risk
of death by 23% compared with placebo or observation (HR, 0.77;
95% CI, 0.65 to 0.91; P = .002). The median OS time was
111.0 months with lenalidomide maintenance compared with
86.9 months with placebo or observation. The median duration of
follow-up among all surviving patients was 88.8 months (range,
0 to 119.8 months). Heterogeneity in OS across studies was not
detected by the Pignon test with the longer follow-up (P = .10).
PFS2
Median PFS2 was 73.3 months with lenalidomide mainte-
nance compared with 56.7 months with placebo or observation
(HR, 0.72; 95% CI, 0.62 to 0.84; Data Supplement). Lenalidomide
maintenance reduced the risk of a PFS2 event (progression on
second-line treatment or death) by 28% compared with placebo or
observation. The PFS2 HRs in all studies favored lenalidomide
maintenance versus placebo or observation (Data Supplement).
Second-Line Antimyeloma Treatment
Time to second-line antimyeloma treatment was prolonged
with lenalidomide maintenance versus placebo or observation
(HR, 0.57; 95% CI, 0.49 to 0.66; Data Supplement). Fewer patients
in the lenalidomide maintenance group (52.6%) started second-
line antimyeloma therapy compared with patients in the placebo or
observation group (70.8%). The most common second-line anti-
myeloma treatment was lenalidomide based (27.9%) in the placebo
or observation group and bortezomib based (19.5%) in the lenali-
domide maintenance group.
Safety
Treatment-emergent adverse events (TEAEs) were analyzed
for patients in the CALGB and IFM trials. Data were not available
from GIMEMA. Rates of treatment discontinuation as a result of
TEAEs were 29.1% in the lenalidomide maintenance group and
12.2% in the placebo or observation group (Table 3). The most
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$ 1 year 150 (67.0) 95 (43.0) 46 (60.5) 217 (70.9) 119 (100) 211 (69.9) 44 (78.6) 51 (76.1) 411 (70.1) 391 (66.3)
$ 2 years 116 (51.8) 32 (14.5) 33 (43.4) 170 (55.6) 119 (100) 121 (40.1) 33 (58.9) 36 (53.7) 319 (54.4) 230 (39.0)
$ 3 years 82 (36.6) 6 (2.7) 24 (31.6) 88 (28.8) 74 (62.2) 32 (10.6) 29 (51.8) 23 (34.3) 199 (34.0) 95 (16.1)
$ 4 years 54 (24.1) 1 (0.5) 18 (23.7) 11 (3.6) 11 (9.2) 2 (0.7) 24 (42.9) 17 (25.4) 89 (15.2) 44 (7.5)
NOTE. Safety population includes patients who received at least one dose of study drug.
Abbreviations: CALGB, Cancer and Leukemia Group B; GIMEMA, Gruppo Italiano Malattie Ematologiche dell’Adulto; IFM, Intergroupe Francophone du Myélome; Len,
lenalidomide.
*In the IFM study, data from two cycles of lenalidomide consolidation are included.
†In the CALGB study, after study unblinding on December 17, 2009, patients randomly assigned to the placebo arm were allowed to cross over to lenalidomide before
progressive disease.
‡In the IFM study, treatment was stopped in the lenalidomide arm in January 2011 for 119 patients (minimum treatment duration of 27 months) after observing an
imbalance of second primary malignancies in the lenalidomide arm.
§Only mean values are reported due to treatment time truncation from the IFM 2005-02 study and median times cannot be given for the IFM 2005-02 study.
3282 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
McCarthy et al
Downloaded from ascopubs.org by 31.157.41.148 on March 5, 2020 from 031.157.041.148
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
common TEAEs leading to treatment discontinuation in the
lenalidomide maintenance and placebo or observation groups were
blood and lymphatic system disorders (4.3% v 2.1%, respectively)
and general disorders and administration site conditions (4.7% v
1.5%, respectively). Consistent with previous CALGB and IFM
reports, this analysis showed a higher frequency of SPMs with
HR (95% CI)
0.38 (0.29 to 0.50)
0.53 (0.43 to 0.64)
0.50 (0.31 to 0.80)
0.48 (0.41 to 0.55)
CALGB (n = 460)
IFM (n = 614)
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Male 322 349 0.40 (0.32 to 0.48)
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Fig 1. Progression-free survival (PFS) analysis (intent-to-treat population). For analyses of PFS, patientswho started another antimyeloma therapy before documented disease
progression or patients with missing assessments are censored. (A) Kaplan-Meier estimates of PFS. (B) Hazard ratios (HRs) for PFS by individual study. (C) HRs for PFS by
subgroup. (*) The size of each blue box corresponds to the size of the individual study. The CI is a function of the overall sample size. (†) Age at randomassignmentwas available
and used for the Cancer and Leukemia Group B (CALGB) 100104 study19 and the Intergroupe Francophone du Myélome (IFM) 2005-02 study20. Only age at diagnosis was
available for the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) RV-MM-PI-209 study2. (‡) The International Staging System (ISS) stage was based on
b2-microglobulin and albumin at diagnosis for the GIMEMA and IFM studies and at registration for the CALGB study. (§) Upon central review, four patients did not meet the
criteria for stable disease (SD). ASCT, autologous stem-cell transplantation; CR, complete response; Len, lenalidomide; PR, partial response; VGPR, very good partial response.
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lenalidomide maintenance versus placebo or observation. Fre-
quencies of hematologic SPMs occurring before PD (5.3% and
0.8% for lenalidomide and placebo or observation, respectively)
and before and after PD (6.1% and 2.8% for lenalidomide and
placebo or observation, respectively) were reported for both
groups. In the lenalidomide maintenance and placebo or obser-
vation groups, frequencies of solid tumor SPMs occurring before
PD (5.8% and 2.0%, respectively) and before and after PD (7.3%
and 4.2%, respectively) were also reported. The cumulative in-
cidence curves for hematologic and solid tumor SPMs are shown in
Figures 3A and 3B. Time to invasive SPMs occurring before PD or
start of second-line therapy was shorter in the lenalidomide
maintenance group versus the placebo or observation group (HR,
2.67; 95% CI, 1.54 to 4.62; P , .001), whereas time to PD or
B
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Fig 2. Overall survival (OS) analysis (intent-to-treat population). (A) Kaplan-Meier estimates of OS. (B) Hazard ratios (HRs) for OS by subgroup. (C) HRs for OS by prior
induction subgroup. (D) HRs for OS by individual study. (*) Age at random assignment was available or used for the Cancer and Leukemia Group B (CALGB) 100104 study19
and the Intergroupe Francophone du Myélome (IFM) 2005-02 study20. Only age at diagnosis was available for the Gruppo Italiano Malattie Ematologiche dell’Adulto
(GIMEMA) RV-MM-PI-209 study2. (†) The International Staging System (ISS) stage was based on b2-microglobulin and albumin at diagnosis for the GIMEMA and IFM
studies and at registration for the CALGB study. (‡) Upon central review, four patients did not meet the criteria for stable disease (SD). (§) All patients in the GIMEMA study
received lenalidomide-based induction, which could be used in combination with any other drug. The size of each blue box corresponds to the size of the individual study.
The CI is a function of the overall sample size. ASCT, autologous stem-cell transplantation; CR, complete response; Len, lenalidomide; NR, not reached; PR, partial
response; TD, thalidomide and dexamethasone; VAD, vincristine, doxorubicin, and dexamethasone; VD, bortezomib and dexamethasone; VGPR, very good partial
response.
3284 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
McCarthy et al
Downloaded from ascopubs.org by 31.157.41.148 on March 5, 2020 from 031.157.041.148
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
second-line therapy was longer with lenalidomide maintenance
versus placebo or observation (HR, 0.51; 95% CI, 0.45 to 0.59; P,
.001; Fig 3C). The risk of developing PD was higher than the risk of
developing an invasive SPM in both groups. In the lenalidomide
maintenance and placebo or observation groups, the cumulative
incidence rates of PD or second-line therapy were consistently
higher than that of invasive SPM over time (Data Supplement).
The time to death as a result of MM was significantly longer in the
lenalidomide maintenance group versus the placebo or observation
group (HR, 0.66; 95% CI, 0.53 to 0.81; P, .001; Fig 3D). For time
to death as a result of SPM or adverse event, there were no dif-
ferences between the two groups.
DISCUSSION
An improved PFS with lenalidomide maintenance versus placebo
or observation after HDM and ASCT in patients with NDMM
was previously reported in the three studies analyzed in this
report.2,19,20 The studies were not powered for OS, and OS data
were not mature at the time of their initial publications. One trial,
the CALGB trial, showed an early significant improvement in OS
with lenalidomide maintenance. As a result of the increased SPM
incidence with lenalidomide maintenance versus placebo reported
in two of the trials, the CALGB and IFM trials, it was important to
understand the risks and benefits of long-term lenalidomide
maintenance after HDM and ASCT for patients with NDMM. The
meta-analysis was planned to demonstrate a 20-month im-
provement in median OS based on an estimated median OS of
70 months with placebo or observation, approximating an HR of
0.78. The OS analysis was planned before identifying studies for
data collection. Primary-source patient data from the three studies
meeting the prespecified inclusion criteria were analyzed. The three
studies consisted of generally similar patient populations, study
designs, and maintenance approaches. The aggregate patient
population provided sufficient power for the OS end point. A
limitation of this analysis is the small number of studies included.
Nevertheless, the meta-analysis was adequately powered to detect
a treatment effect and demonstrated that lenalidomide mainte-
nance versus placebo or observation after HDM and ASCT sig-
nificantly prolonged OS and reduced the risk of death by 25%.
A 29.3-month PFS improvement was observed with lenali-
domide maintenance versus placebo or observation on an ITT
basis; these results are not adjusted for the crossover of placebo arm
patients without PD in the CALGB study. The PFS2 benefit with
lenalidomide maintenance versus placebo or observation indicated
that lenalidomide maintenance did not induce PD resistant to
salvage treatment. The PFS improvements observed with lenali-
domide maintenance in each study were similar despite different
dosing schedules (days 1 to 28 of a 28-day schedule for CALGB and
IFM and days 1 to 21 of a 28-day schedule for GIMEMA). The
recently presented results from the Myeloma XI trial demonstrated
a similar PFS improvement with lenalidomide maintenance versus
observation (HR, 0.47; 95% CI, 0.38 to 0.60) after ASCT using
a treatment schedule of 21 days of treatment in a 28-day schedule.26
The PFS subgroup analyses consistently favored lenalidomide
maintenance versus placebo or observation, with differences in the
magnitude of benefit. For the OS subgroup analyses, the bene-
fit with lenalidomide maintenance was heterogeneous. The OS
benefit with lenalidomide maintenance was less pronounced for
patients older than age 60 years and for women. Patients with ISS
disease stage III did not experience an OS benefit. The risk of death
was reduced by 30% and 37% with lenalidomide maintenance
versus placebo or observation in patients achieving very good partial
Table 3. Discontinuations as a Result of TEAEs (safety population)
TEAE














$ 1 TEAE leading to discontinuation 63 (28.1) 19 (8.6) 91 (29.7) 45 (14.9) 154 (29.1) 64 (12.2)
TEAEs leading to discontinuation ($ 1% of all patients)‡
Blood and lymphatic system disorder 11 (4.9) 4 (1.8) 12 (3.9) 7 (2.3) 23 (4.3) 11 (2.1)
Neutropenia 5 (2.2) 0 7 (2.3) 1 (0.3) 12 (2.3) 1 (0.2)
Thrombocytopenia 6 (2.7) 1 (0.5) 3 (1.0) 5 (1.7) 9 (1.7) 6 (1.1)
General disorders and administration site conditions 12 (5.4) 5 (2.3) 13 (4.2) 3 (1.0) 25 (4.7) 8 (1.5)
Adverse event not specified 10 (4.5) 4 (1.8) 0 0 10 (1.9) 4 (0.8)
Neoplasms: benign, malignant, and unspecified§ 16 (7.1) 3 (1.4) 7 (2.3) 2 (0.7) 23 (4.3) 5 (1.0)
Skin and subcutaneous tissue disorders 6 (2.7) 1 (0.5) 12 (3.9) 9 (3.0) 18 (3.4) 10 (1.9)
Nervous system disorders 5 (2.2) 3 (1.4) 13 (4.2) 6 (2.0) 18 (3.4) 9 (1.7)
GI disorders 5 (2.2) 0 13 (4.2) 1 (0.3) 18 (3.4) 1 (0.2)
Diarrhea 5 (2.2) 0 6 (2.0) 0 11 (2.1) 0
Infections and infestations 4 (1.8) 0 5 (1.6) 4 (1.3) 9 (1.7) 4 (0.8)
Musculoskeletal and connective tissue disorders 1 (0.4) 1 (0.5) 5 (1.6) 6 (2.0) 6 (1.1) 7 (1.3)
NOTE. Safety population includes patients who received at least one dose of study drug.
Abbreviations: CALGB, Cancer and Leukemia Group B; GIMEMA, Gruppo Italiano Malattie Ematologiche dell’Adulto; IFM, Intergroupe Francophone duMyélome; Len;
lenalidomide; TEAE, treatment-emergent adverse event.
*In the IFM study, data from two cycles of lenalidomide consolidation are included.
†Data from the IFM and CALGB studies only.
‡System organ class presented with preferred terms nested below.
§Includes cysts and polyps.
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C
No. at risk:
 Len maintenance: time to invasive SPM
before PD or second-line therapy 586 490 403 314 245 196 125 65 12 0
Placebo/observation: time to invasive SPM
before PD or second-line therapy 601 434 282 195 142 98 59 31 5 0
Len maintenance: time to PD or second-line 
therapy
586 498 414 335 268 219 144 79 15 0
Placebo/observation: time to PD or
second-line therapy






















Len maintenance: time to invasive SPM before PD or second-line therapy HR, 2.67 (95% CI, 1.54 to 4.62)
P < .001
HR, 0.51 (95% CI, 0.45 to 0.59)
 P < .001
Placebo/observation: time to invasive SPM before PD or second-line therapy
Len maintenance: time to PD or second-line therapy
Placebo/observation: time to PD or second-line therapy 
Time to Event (months)



























586 559 512 463 420 366 251 139 38 1
Placebo/
observation
601 558 525 469 428 340 248 119 28 0
HR, 2.03 (95% CI, 1.14 to 3.61)





586 554 506 456 413 361 251 136 35 0






















Time to Solid Tumor SPM Onset (months)


























Time to Death (months) 
No. at risk:
Len maintenance: caused by MM 605 577 555 508 473 431 385 282 200 95 20 1 0
Len maintenance: caused by SPM 605 577 555 508 473 431 385 282 200 95 20 1 0
Len maintenance: caused by AE 605 577 555 508 473 431 385 282 200 95 20 1 0
Placebo/observation: caused by MM 603 569 542 505 459 425 351 270 174 71 10 0
Placebo/observation: caused by SPM 603 569 542 505 459 425 351 270 174 71 10 0
Placebo/observation: caused by AE 603 569 542 505 459 425 351 270 174 71 10 0
0 10 20 30 40 50 60 70 80 90 100 110 120
Len maintenance: caused by MM
Len maintenance: caused by SPM
Len maintenance: caused by AE
Placebo/observation: caused by MM
Placebo/observation: caused by SPM
Placebo/observation: caused by AE
Time to death caused by MM with
Len maintenance v placebo/observation:
HR, 0.66 (95% CI, 0.53 to 0.81); P < .001  
Fig 3. Second primary malignancy and mortality analyses. (A) Cumulative incidence curve of time to hematologic second primary malignancy (SPM) onset (as-treated
population). Patients who were randomly assigned but not treated with lenalidomide maintenance are included in the control group. (B) Cumulative incidence of time to
solid tumor SPM onset (as-treated population). Patients who were randomly assigned but not treated with lenalidomide maintenance are included in the control group. (C)
Cumulative incidence curves of time to disease progression and time to invasive SPM onset before disease progression. (D) Kaplan-Meier (KM) curve of time to death by
cause of death. AE, adverse event; Len, lenalidomide; MM, multiple myeloma; PD, progressive disease.
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response or complete response, respectively. The induction sub-
group analyses for OS favored lenalidomide maintenance versus
placebo or observation. The effect was less favorable in patients who
received a thalidomide-containing induction regimen or a vincris-
tine, doxorubicin, and dexamethasone induction regimen. A PFS
benefit, but not an OS benefit was seen with lenalidomide main-
tenance versus placebo or observation in patients with high-risk
cytogenetics. Only a small number of patients had adverse-risk
cytogenetics (n = 92). The Myeloma XI trial demonstrated im-
proved PFS with lenalidomide maintenance versus observation in
patients with high-risk cytogenetics, which included patients who
had and had not received ASCTas a result of eligibility. The data are
not yet mature enough for an OS analysis.26
The heterogeneity analysis demonstrated that all three studies
contributed to the positive results of the meta-analysis. The HRs
for each study are consistent with an OS improvement with
lenalidomide maintenance versus placebo or observation. The
quantitative heterogeneity results from the differences in magni-
tude of the treatment effect among the studies, particularly be-
tween the CALGB and IFM studies. Possible reasons for this
heterogeneity include differences in and incomplete data for some
patient demographics, different induction regimens, number of
ASCTs, consolidation therapy after ASCT in the IFM study, dis-
continuation of lenalidomide maintenance before PD in the IFM
study, crossover from placebo to lenalidomide maintenance in the
CALGB study for patients without progression, and differences in
frequency and type of second-line therapy.
There were differences in the length of maintenance therapy in
the three studies. The IFM study stopped lenalidomide mainte-
nance at a mean duration of approximately 2 years. For the IFM
study patients who stopped lenalidomide maintenance without
progression (n = 119) the mean duration of maintenance was 3.3
years. The mean durations of maintenance in the CALGB and
GIMEMA studies were 2.5 and 3 years, respectively. The pro-
portions of patients on lenalidomide maintenance across the three
studies are similar in the treatment duration categories of$ 1,$ 2,
and $ 3 years. The cessation of lenalidomide maintenance in the
IFM study is the primary reason for the smaller percentage of
patients on lenalidomide maintenance at$ 4 years compared with
the other studies. These duration differences may have influenced
the magnitude of improvement in PFS, OS, and PFS2 but did not
seem to reduce salvage treatment efficacy after PD. A recent ret-
rospective analysis showed a correlation between length of lena-
lidomide maintenance therapy after ASCT and length of OS in
patients with NDMM.27 None of these studies examined a pre-
determined maintenance duration. Future study designs may evaluate
different lengths of maintenance therapy, particularly in patients who
achieve minimal residual disease–negative status.
In this analysis, the incidence rates of hematologic and solid
tumor SPMs with lenalidomide maintenance were higher com-
pared with placebo or observation. At a median follow-up time of
79.5 months, the rates of hematologic and solid tumor SPMs
with lenalidomide maintenance before PD were 5.3% and 5.8%,
respectively. These results are comparable to a previous meta-
analysis of lenalidomide therapy in patients with NDMM that
showed cumulative 5-year incidence rates of hematologic and solid
tumor SPMs of 3.1% and 3.8%, respectively.28 The cumulative
incidence rate of developing an SPM before PD is higher for
patients who received lenalidomide maintenance, and the cu-
mulative incidence rates of PD and death as a result of MM are
higher for patients who received placebo or observation. Overall,
the risk of developing PD is greater than that of developing an
SPM.
An important treatment goal for patients with NDMM is to
achieve and maintain remission or long-term disease control.29,30
Maintenance therapy after ASCT can be considered a valid ap-
proach toward achieving long-term disease control, delaying time
to relapse and second-line treatment, and prolonging survival. A
previously published meta-analysis of RCTs comparing thalido-
mide- or lenalidomide-based maintenance versus thalidomide-
and lenalidomide-free maintenance or no maintenance therapy
showed in stratified analyses that both maintenance therapies
improve PFS, but not OS, in the transplantation setting.31 The
study used published data from 2012 and 2014 of the same three
trials in this analysis. The OS data were less mature, and the analysis
did not use primary-source, patient-level data.
This study demonstrates a statistically significant and clinically
meaningful improvement in OS with lenalidomide maintenance.
With new, highly active, triplet induction regimens enhancing
depth and duration of response as well as ongoing studies eval-
uating the optimal timing of ASCT,32-36 the use of lenalidomide
maintenance for transplantation-eligible patients can be consid-
ered a standard of care. The costs of maintenance therapy should be
weighed against the costs of shorter survival, earlier progression,
and earlier use of subsequent lines of therapies for patients without
maintenance. Understanding the role of minimal residual dis-
ease detection and immune reconstitution after ASCT, as well
as developing early end points as surrogates for long-term out-
comes, should allow us to develop clinical strategies to further
improve OS.
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